Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF

Natural killer cell stimulatory factor (NKSF) is a 70-kD heterodimeric cytokine that was initially isolated from conditioned medium of human B lymphoblastoid cell lines. The effects of recombinant NKSF on the function of human peripheral blood NK cells were examined. NKSF directly augmented the cytolytic activity of freshly isolated NK cells. Both CD56dim and CD56bright NK cells demonstrated enhanced cytotoxicity after brief exposure to NKSF. In contrast, highly purified T lymphocytes did not exhibit major histocompatibility complex- unrestricted cytotoxicity after short-term culture with NKSF. Like interleukin 2 (IL-2), NKSF augmented the lysis of NK-sensitive, NK- resistant, and antibody-coated targets. Both NKSF and IL-2 induced marked upregulation of several NK cell adhesion molecules known to participate in cytolysis, including CD2, CD11a, and CD54. However, NKSF activates NK cells through a pathway distinct from that of IL-2, since the presence of anti-IL-2 receptor (anti-IL-2R) antibodies or IL-4 did not inhibit the effects of NKSF. NKSF by itself induced very little proliferation of resting NK cells. NK cells preactivated in vitro with IL-2 demonstrated enhanced proliferation to NKSF, but the degree of proliferation was always inferior to that induced by IL-2 alone. Moreover, NKSF strongly inhibited IL-2-induced proliferation of either resting or preactivated NK cells. This inhibition was not the result of decreased IL-2R expression, because NKSF-activated NK cells expressed higher levels of both IL-2Rs p75 and p55. Furthermore, NKSF did not inhibit the proliferation of mitogen-activated T cells, indicating a selective effect on NK cell proliferation. Human NK cells expanded in vivo by prolonged continuous infusions of IL-2 remained fully responsive to NKSF. Picomolar concentrations of NKSF were as effective as nanomolar concentrations of IL-2 in augmenting the cytolytic activity of NK cells expanded in vivo by IL-2. NKSF may play an important role in the regulation of human NK cell function, and its possible use as a therapeutic cytokine deserves further investigation.

[1]  J. Ritz,et al.  Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells , 1992, European journal of immunology.

[2]  F. Podlaski,et al.  Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). , 1991, Journal of immunology.

[3]  D. Cosman,et al.  Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extracellular domain of the interleukin-6 receptor , 1991, Cell.

[4]  P. Familletti,et al.  Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Hewick,et al.  Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. , 1991, Journal of immunology.

[6]  G. Trinchieri,et al.  Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers , 1991, The Journal of experimental medicine.

[7]  J. Ritz,et al.  Biology and clinical relevance of human natural killer cells. , 1990, Blood.

[8]  C. Gahmberg,et al.  Participation of CD11a‐c/CD18, CD2 and ROD‐binding receptors in endogenous and interleukin‐2‐stimulated NK activity of CDS‐negative large granular lymphocytes , 1990, International journal of cancer.

[9]  M. Caligiuri,et al.  Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. , 1990, Journal of immunology.

[10]  F. Podlaski,et al.  Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Caligiuri,et al.  Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors , 1990, The Journal of experimental medicine.

[12]  T. Uchiyama,et al.  Selective expression of the p70 subunit of the interleukin-2 receptor on lymphocytes from patients with infectious mononucleosis. , 1990, Blood.

[13]  R. Kaufman Strategies for obtaining high level expression in mammalian cells. , 1990 .

[14]  G. Trinchieri,et al.  Biology of Natural Killer Cells , 1989, Advances in Immunology.

[15]  L. Lanier,et al.  Comparative studies of human FcRIII-positive and negative natural killer cells. , 1989, Journal of immunology.

[16]  W. Linehan,et al.  Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.

[17]  G. Trinchieri,et al.  Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes , 1989, Journal of Experimental Medicine.

[18]  R. Fisher,et al.  Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Fisher,et al.  A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Jones,et al.  Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Gahmberg,et al.  CD11a-c/CD18 and GP84 (LB-2) adhesion molecules on human large granular lymphocytes and their participation in natural killing. , 1988, Journal of immunology.

[22]  R. Bechhofer,et al.  Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. , 1988, Cancer research.

[23]  W. Greene,et al.  Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells. , 1988, The Journal of clinical investigation.

[24]  L. Lanier,et al.  In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  W. Leonard,et al.  The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. , 1987, Science.

[26]  W. Chan,et al.  The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[27]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[28]  E. Reinherz,et al.  Enhancement of natural killer function through activation of the T11 E rosette receptor. , 1987, The Journal of clinical investigation.

[29]  K C Zoon,et al.  Interferons and their actions. , 1987, Annual review of biochemistry.

[30]  G. Trinchieri,et al.  Induction of proliferation in vitro of resting human natural killer cells: IL 2 induces into cell cycle most peripheral blood NK cells, but only a minor subset of low density T cells. , 1986, Journal of immunology.

[31]  L. Lanier,et al.  Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis , 1986, The Journal of experimental medicine.

[32]  S. Rosenberg,et al.  Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. , 1985, Cancer research.

[33]  E. Reinherz,et al.  Analysis of T-cell receptor gene rearrangement and expression in human natural killer clones. , 1985, Science.

[34]  L. Lanier,et al.  Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens. , 1985, Journal of immunology.

[35]  C. Balch,et al.  Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells. , 1985, Journal of immunology.

[36]  G. Trinchieri,et al.  Response of resting human peripheral blood natural killer cells to interleukin 2 , 1984, The Journal of experimental medicine.

[37]  S. Rosenberg,et al.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. , 1984, Science.